Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range

Cellular and Molecular Neurobiology

Volumn 27, Issue 8, 2007, Pages 1127-1145

  Majumder, Pritha ^a   Raychaudhuri, Swasti ^a   Chattopadhyay, Biswanath ^a,b   Bhattacharyya, Nitai P ^a  

^a SAHA INSTITUTE OF NUCLEAR PHYSICS   (India)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Huntington's disease; Minocycline; Poly Q aggregates

Indexed keywords

CALPAIN; CASPASE; CASPASE 2; CASPASE 8; CASPASE 9; HUNTINGTIN; INTERLEUKIN 1BETA CONVERTING ENZYME; MINOCYCLINE; MITOCHONDRIAL COMPLEX II ENZYME; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; EXON; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; CALPAIN; CASPASE 2; CELL SURVIVAL; CELLS, CULTURED; CYTOCHROMES C; DNA FRAGMENTATION; ELECTRON TRANSPORT COMPLEX II; ENZYME ACTIVATION; EXONS; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; HUNTINGTON DISEASE; MICE; MITOCHONDRIA; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TRINUCLEOTIDE REPEATS;

EID: 38649110478     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10571-007-9220-7     Document Type: Conference Paper

References (47)

1. Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N, Saudou F, Elalouf JM, Hirsch E, Hantraye P, Deglon N, Brouillet E (2006) Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell 17:1652-1663
2. Bizat N, Hermel JM, Humbert S, Jacquard C, Creminon C, Escartin C, Saudou F, Krajewski S, Hantraye P, Brouillet E (2003) In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3. J Biol Chem 278:43245-43253
3. Brennan WA Jr, Bird ED, Aprille JR (1985) Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 44:1948-1950
4. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41:646-653
5. Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martin-Ibanez R, Munoz MT, Mengod G, Ernfors P, Alberch J (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci 24:7727-7739
6. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha J, Friedlander RM (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797-801
7. Conrad CA, Tiina MK, Andreu VV, Raymond AS (2006) Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentration. Proc Natl Acad Sci USA 103:9685-9690
8. Cowan CM, Raymond LA (2006) Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol 75:25-71
9. Dragunow M, Faull RL, Lawlor P, Beilharz EJ, Singleton K, Walker EB, Mee E (1995) In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 6:1053-1057
10. Feng L, Lin T, Uranishi H, Gu W, Xu Y (2005) Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol 25:5389-5395
11. Gafni J, Ellerby LM (2002) Calpain activation in Huntington's disease. J Neurosci 22:4842-4849
12. Gervais FG, Singaraja R, Xanthoudakis S, Gutekunst CA, Leavitt BR, Metzler M, Hackam AS, Tam J, Vaillancourt JP, Houtzager V, Rasper DM, Roy S, Hayden MR, Nicholson DW (2002) Recruitment and activation of caspase-8 bythe Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat Cell Biol 4:95-105
13. Goffredo D, Rigamonti D, Tartari M, De-Micheli A, Verderio C, Matteoli M, Zuccato C, Cattaneo E (2002) Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons. J Biol Chem 277:39594-39598
14. Gomez GT, Hu H, McCaw EA, Denovan-Wright EM (2006) Brain-specific factors in combination with mutant huntingtin induce gene-specific transcriptional dysregulation. Mol Cell Neurosci 31:661-675
15. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39:385-389
16. Guegan C, Vila M, Teismann P, Chen C, Onteniente B, Li M, Friedlander RM, Przedborski S (2002) Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALS. Mol Cell Neurosci 20:553-562
17. Gupta S, Radha V, Furukawa Y, Swarup G (2001) Direct transcriptional activation of human caspase1 by tumor suppressor p53, J. Biol Chem 276:10585-105858
18. Hackam AS, Yassa AS, Singaraja R, Metzler M, Gutekunst C-A, Gan L, Warby S, Wellington CL, Vaillancourt J, Chen N, Gervais FG, Raymond L, Nicholson DW, Hayden MR (2000) Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain. J Biol Chem 275:41299-41308
19. Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, Hook V, Singaraja R, Krajewski S, Goldsmith PC, Ellerby HM, Hayden MR, Bredesen DE, Ellerby LM (2004) Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ 11:424-438
20. Ho LW, Brown R, Maxwell M, Wyttenbach A, Rubinsztein DC (2001) Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease. J Med Genet 38:450-452
21. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neuro degeneration. Neuron 23:181-192
22. Kim M, Lee HS, LaForet G, McIntyre C, Martin EJ, Chang P, Kim. TW, Williams M, Reddy PH, Tagle D, Boyce FM, Won L, Heller A, Aronin N, DiFiglia M (1999) Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 19:964-973
23. Li SH, Lam S, Cheng AL, Li XJ (2000) Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. Hum Mol Genet 9:2859-2867
24. Lu CX, Fan TJ, Hu GB, Cong RS (2003) Apoptosis-inducing factor and apoptosis. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 35:881-885
25. Majumder P, Chattopadhyay B, Mazumder A, Das P, Bhattacharyya NP (2006) Induction of apoptosis in cells expressing exogenous Hippi, a molecular partner of huntingtin-interacting protein HIP1. Neurobiol Dis 22:242-256
26. Mann VM, Cooper JM, Javoy-Agid F, Agid Y, Jenner P, Schapira AH (1990) Mitochondrial function and parental sex effect in Huntington's disease. Lancet 336:749
27. Narain Y, Wyttenbach A, Rankin J, Furlong RA, Rubinsztein DC (1999) A molecular investigation of true dominance in Huntington's disease. J Med Genet 36:739-746
28. Nenguke T, Aladjem MI, Gusella JF, Wexler NS, The Venezuela HD Project, Arnheim N (2003) Candidate DNA replication initiation regions at human trinucleotide repeat disease loci. Hum Mol Genet 12:1021-1028
29. Omi K, Hachiya NS, Tokunaga K, Kaneko K (2005) siRNA-mediated inhibition of endogenous Huntington disease gene expression induces an aberrant configuration of the ER network in vitro. Biochem Biophys Res Commun 338:1229-1235
30. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li XJ, Stieg PE, Yuan J, Penney JB, Young AB, Cha JH, Friedlander RM (1999) Inhibition of caspase1 slows disease progression in a mouse model of Huntington's disease. Nature 399:263-267
31. Puranam KL, Wu G, Strittmatter WJ, Burke JR (2006) Polyglutamine expansion inhibits respiration by increasing reactive oxygen species in isolated mitochondria. Biochem Biophys Res Commun 341:607-613
32. Read SH, Baliga BC, Ekert PG, Vaux DL, Kumar S (2002) A novel Apaf-1-independent putative caspase-2 activation complex. J Cell Biol 159:739-745
33. Rigamonti D, Sipione S, Goffredo D, Zuccato C, Fossale E, Cattaneo E (2001) Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J Biol Chem 276:14545-14548
34. Ruan Q, Lesort M, MacDonald ME, Johnson GV (2004) Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum Mol Genet 13:669-681
35. Sanchez I, Xu CJ, Juo P, Kakizaka A, Biens J, Yuan J (1999) Caspase 8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22:623-633
36. Tabrizi SJ, Cleeter M, Xuereb J, Taanman JW, Cooper JM, Schapira AH (1999) Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Neurol 45:25-32
37. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM (1995) Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81:801-809
38. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983
39. Thomas LB, Gates DJ, Richfield EK, O'Brien TF, Schweitzer JB, Steindler DA (1995) DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp Neurol 133:265-272
40. Vaisid T, Kosower NS, Barnoy S (2005) Caspase-1 activity is required for neuronal differentiation of PC12 cells: cross-talk between the caspase and calpain systems. Biochim Biophys Acta 1743:223-230
41. Vis JC, Schipper E, de Boer-van HRT, Verbeek MM, de Waal RM, Wesseling P, ten Donkelaar HJ, Kremer B (2005) Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropathol (Berl) 109:321-328
42. Wang GH, Mitsui K, Kotliarova S, Yamashita A, Nagao Y, Tokuhiro S, Iwatsubo T, Kanazawa I, Nukina N (1999) Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. Neuroreport 10:2435-2438
43. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM (2003) Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Nat Acad Sci USA 100:10483-10487
44. Wang X, Wang H, Figueroa BE, Zhang WH, Huo C, Guan Y, Zhang Y, Bruey JM, Reed JC, Friedlander RM (2005) Dysregulation of receptor interacting protein-2 and caspase recruitment domain only protein mediates aberrant caspase-1 activation in Huntington's disease. J Neurosci 25:11645-11654
45. Yang L, Sugama S, Mischak RP, Kiaei M, Bizat N, Brouillet E, Joh TH, Beal MF (2004) A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiol Dis 17:250-259
46. Zemskov EA, Nukina N (2003) Impaired degradation of PKCalpha by proteasome in a cellular model of Huntington's disease. Neuroreport 14:1435-1438
47. Zhang Y, Ona VO, Li M, Drozda M, Dubois-Dauphin M, Przedborski S, Ferrante RJ, Friedlander RM (2003) Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington's disease. J Neurochem 87:1184-1192